Agenda for Day 2 - Tuesday 10 November, 2026
Late-stage investment is where biotech innovation meets the demands of commercialization and global impact. This panel brings together top investors, executives, and industry experts to explore the unique challenges and opportunities of funding biotech companies on the cusp of breakthrough success. From navigating regulatory hurdles to scaling operations and preparing for IPOs or acquisitions, discover how late-stage funding is shaping the trajectory of biotech’s most promising ventures. Gain insider perspectives on the strategies driving growth, the risks involved, and the vision required to turn cutting-edge science into transformative solutions. Don’t miss this deep dive into the high-stakes world of late-stage biotech investment!
- Hubert Birner - Managing Partner, TVM Capital
- Sander Slootweg - Managing Partner, Forbion
For today’s biotech founders, building a company no longer starts with infrastructure it starts with access to the right ecosystem. Incubators backed by global pharma and industry leaders are playing an increasingly central role in shaping the next generation of biotech companies, providing not just space, but capital access, expertise, partnerships, and integrated support networks.
In this fireside chat, a leader from one of the industry’s leading incubator platforms will share what they look for in early-stage companies, how they support founders beyond the lab, and how startups can best leverage ecosystem partnerships to accelerate growth. From navigating early development decisions to building the right partner network, this conversation offers a candid look at how biotech companies are really built today and what founders need to succeed.